Get the Stockscreener App
16.16
6.64%
-1.15
After Hours:
16.13
-0.03
-0.19%
Pulse Biosciences Inc stock is traded at $16.16, with a volume of 330.16K.
It is down -6.64% in the last 24 hours and up +6.18% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$17.31
Open:
$17.43
24h Volume:
330.16K
Relative Volume:
1.91
Market Cap:
$1.09B
Revenue:
-
Net Income/Loss:
$-46.13M
P/E Ratio:
-19.89
EPS:
-0.8123
Net Cash Flow:
$-34.10M
1W Performance:
+9.86%
1M Performance:
+6.18%
6M Performance:
-23.01%
1Y Performance:
-15.35%
1-Day Range:
$15.97
$17.61
1-Week Range:
$14.49
$17.88
52-Week Range:
$13.77
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
16.16 | 1.16B | 0 | -46.13M | -34.10M | -0.8123 |
|
ISRG
Intuitive Surgical Inc
|
480.26 | 171.02B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.94 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
87.71 | 42.93B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
284.89 | 41.69B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.20 | 17.70B | 2.90B | 467.20M | 306.90M | 6.37 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Price action breakdown for Pulse Biosciences Inc.Quarterly Investment Review & Long-Term Safe Return Strategies - Newser
Can you recover from losses in Pulse Biosciences Inc.Exit Point & Expert Approved Momentum Ideas - Newser
Smart tools for monitoring Pulse Biosciences Inc.’s price action2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
What high frequency data says about Pulse Biosciences Inc.2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
How moving averages guide Pulse Biosciences Inc. tradingJuly 2025 Chart Watch & Community Trade Idea Sharing Platform - Newser
How Interest Rate Changes Impact Pulse Biosciences Inc. Stock PerformanceJuly 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Using flow based indicators on Pulse Biosciences Inc.July 2025 Patterns & Daily Technical Stock Forecast Reports - Newser
Pulse Biosciences Inc. Company Revenue and Profit Trends: A Deep Dive2025 Key Lessons & Safe Capital Allocation Plans - Newser
Custom watchlist performance reports with Pulse Biosciences Inc.July 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Short interest data insights for Pulse Biosciences Inc.Weekly Volume Report & Low Risk Entry Point Tips - Newser
Volume spikes in Pulse Biosciences Inc. stock – what they meanJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - Newser
What to expect from Pulse Biosciences Inc. in the next 30 daysMarket Sentiment Report & Weekly Top Performers Watchlists - Newser
Pulse Biosciences outlines initial percutaneous electrode revenue and IDE milestones while expanding nsPFA clinical programs - MSN
When is the best time to buy Pulse Biosciences Inc. stock2025 Retail Activity & AI Forecasted Stock Moves - Newser
Pulse Biosciences Reports Q2 2025 Earnings: Advancements in Clinical Programs and Strong Cash Position - AInvest
Pulse Biosciences shares surpass 200 DMA, rising 4.9% on Thursday. - AInvest
Pulse Biosciences (PLSE) Shares Cross Above 200 DMA - Nasdaq
Pulse Biosciences Inc. stock momentum explainedWeekly Trend Summary & Technical Entry and Exit Alerts - Newser
Will Pulse Biosciences Inc. see short term momentumBuy Signal & Verified Short-Term Plans - Newser
Competitive Positioning of Pulse Biosciences Inc.: Is It Leading or LaggingPortfolio Value Report & Accurate Trade Setup Notifications - Newser
Pulse Biosciences Surges 10.2% Amid Biotech Sector Turmoil: What's Fueling the Rally? - AInvest
Pulse Biosciences at Canaccord Conference: Strategic Expansion in Ablation By Investing.com - Investing.com Canada
Is it time to cut losses on Pulse Biosciences Inc.Long Setup & Real-Time Chart Breakout Alerts - Newser
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2025 Earnings Call Transcript - Insider Monkey
Pulse Biosciences Cash Jumps in Q2 - AOL.com
Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: Navigating Increased Expenses ... - Yahoo Finance
Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: N - GuruFocus
Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: Navigating Increased Expenses ... By GuruFocus - Investing.com Canada
Pulse Biosciences Reports Q2 2025 Progress and Results - TipRanks
Decoding Pulse Biosciences Inc (PLSE): A Strategic SWOT Insight - GuruFocus
Pulse Biosciences' Q2 2025: Unraveling Contradictions in Partnerships, R&D, and Clinical Strategies - AInvest
Pulse Biosciences Q2 2025 Earnings Call Transcript - MarketBeat
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results - BioSpace
Pulse Biosciences Reports Q2 2025 Earnings, Outlines Percutaneous Electrode Revenue and IDE Milestones - AInvest
Evaluating Pulse Biosciences (PLSE) as a Speculative Play on Clinical Catalysts in nsPFA Technology - AInvest
Earnings call transcript: Pulse Biosciences Q2 2025 results show increased costs - Investing.com Nigeria
Transcript : Pulse Biosciences, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Pulse Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pulse Biosciences Q2 Loss Widens - MarketScreener
PULSE BIOSCIENCES Earnings Results: $PLSE Reports Quarterly Earnings - Quiver Quantitative
Pulse Biosciences Misses Q2 EPS Estimate by $0.02, Cash at $106.3M as of June 30. - AInvest
Can Pulse Biosciences Inc. be the next market leaderReal Profit Trade Tracker - newsyoung.net
Pulse Biosciences Inc. recovery potential after sell offTechnical Screener for High Growth Stocks - Newser
Best data tools to analyze Pulse Biosciences Inc. stockFree High Return Stock Focus With Safety - Newser
What Fibonacci levels say about Pulse Biosciences Inc. reboundAI-Based Signal Detection for Active Traders - Newser
Order flow analysis tools used on Pulse Biosciences Inc.Volume Confirmed Setup with Entry Confidence - Newser
Published on: 2025-08-13 00:39:39 - Newser
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| UECKER DARRIN | Chief Technology Officer |
Jun 13 '25 |
Sale |
15.98 |
15,000 |
239,700 |
122,872 |
0.31%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):